Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
OBJECTIVE
To assess whether, in GnRH agonist IVF cycles where there is a risk of ovarian hyperstimulation syndrome (OHSS), the addition of cabergoline to the hydroxyethyl starch (HES) infusion could decrease OHSS incidence and severity.


METHODS
Prospective randomized study. The population under study consisted of women undergoing IVF cycles with GnRH agonist protocols, at risk of OHSS (more than 20 follicles observed larger than 12 mm in diameter and/or estradiol levels of 3000-5000 pg/mL). Women received a slow infusion of 500 mL of 6% HES during follicular aspiration alone or combined with 0.5mg cabergoline administration for 8 days, starting on the day of hCG administration.


RESULTS
The rates of OHSS (both early and late) were very similar in the HES alone group (3.19% (3/94)) and in the HES plus cabergoline group (5.68% (5/88)), as were the rates of severe cases of OHSS (1.06% and 2.27%). Pregnancy rates (PR) were also similar in the two groups (ongoing PR per transfer, 47.56% and 47.50%).


CONCLUSIONS
The co-administration of cabergoline in patients receiving HES due to OHSS risk did not reduce the rate or severity of OHSS in GnRH agonist IVF cycles.
Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Cruces University Hospital, Vizcaya, Spain; School of Medicine, Basque Country University, Spain.
Roberto
R
Matorras
Maider
M
Andrés
Rosario
R
Mendoza
Begoña
B
Prieto
Jose Ignacio
JI
Pijoan
Antonia
A
Expósito
D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced / Q000517:prevention & control*; D010062:Ovulation Induction / Q000009:adverse effects; D010952:Plasma Substitutes / Q000627:therapeutic use*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D055502:Secondary Prevention; D017329:Triptorelin Pamoate
D018491:Dopamine Agonists; D004873:Ergolines; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D000077465:Cabergoline
Cabergoline; Hydroxyethyl starch; IVF; OHSS; Prevention